How Is Ozempic-Related Gastroparesis Diagnosed in New York?

Latest update (2026-01)

FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]

From General Health Education to Specific Medication Risks

If you're experiencing persistent nausea, vomiting, or abdominal pain after starting Ozempic, you may be wondering whether these symptoms point to gastroparesis. Decades of pharmacovigilance have established that certain medications can slow gastric emptying, and recent reports have brought attention to this potential side effect with GLP-1 receptor agonists. This guide explains the diagnostic process for Ozempic-related gastroparesis in New York, including the symptoms to watch for and the tests your doctor may use.

Understanding Gastroparesis and Its Link to Ozempic

Gastroparesis is a disorder characterized by delayed gastric emptying in the absence of mechanical obstruction, leading to symptoms such as nausea, vomiting, early satiety, and abdominal pain. Clinical diagnosis often involves gastric emptying scintigraphy, which measures the rate at which food leaves the stomach. The condition can significantly impair quality of life and may require dietary modifications, medications, or even surgical interventions. Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for the management of type 2 diabetes mellitus. Its pharmacology involves slowing gastric emptying, which contributes to its glucose-lowering effects. However, this mechanism also underlies the gastrointestinal adverse reactions commonly reported with its use. In placebo-controlled trials, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic than placebo (placebo 15.3%, Ozempic 0.5 mg 32.7%, Ozempic 1 mg 36.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). More patients receiving Ozempic 0.5 mg (3.1%) and Ozempic 1 mg (3.8%) discontinued treatment due to gastrointestinal adverse reactions than patients receiving placebo (0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In a trial with Ozempic 1 mg and 2 mg, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic 2 mg (34.0%) vs Ozempic 1 mg (30.8%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Specific adverse reactions reported in ≥5% of Ozempic-treated patients with type 2 diabetes mellitus include nausea (placebo 6.1%, Ozempic 0.5 mg 15.8%, Ozempic 1 mg 20.3%), vomiting (placebo 2.3%, Ozempic 0.5 mg 5.0%, Ozempic 1 mg 9.2%), diarrhea (placebo 1.9%, Ozempic 0.5 mg 8.5%, Ozempic 1 mg 8.8%), abdominal pain (placebo 4.6%, Ozempic 0.5 mg 7.3%, Ozempic 1 mg 5.7%), and constipation (placebo 1.5%, Ozempic 0.5 mg 5.0%, Ozempic 1 mg 3.1%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). These data highlight the dose-dependent nature of gastrointestinal side effects.

Mechanistic Pathways and Warning Adequacy

Mechanistic pathways linking Ozempic to gastroparesis involve the drug's action on GLP-1 receptors in the gastrointestinal tract, which delays gastric emptying. While this effect is intended for glycemic control, it can become pathological in susceptible individuals, leading to symptomatic gastroparesis. The timeline between exposure and documented harm is variable; symptoms often emerge during dose escalation, but cases of persistent gastroparesis after prolonged use have been reported. The adequacy of warnings regarding Ozempic and gastroparesis is a critical risk anchor. The prescribing information for Ozempic includes warnings about gastrointestinal adverse reactions but does not explicitly list gastroparesis as a specific adverse event. Serious hypersensitivity reactions, such as anaphylaxis and angioedema, have been reported with Ozempic and other GLP-1 receptor agonists (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). However, the label does not provide a dedicated warning for gastroparesis, which may affect the legal assessment of whether manufacturers adequately informed patients and healthcare providers of this risk.

Statute of Limitations for Ozempic Claims in New York

For affected patients in New York, settlement-related considerations must account for the statute of limitations. In New York, the statute of limitations for personal injury claims is generally three years from the date of injury. For product liability cases involving prescription drugs, the clock typically starts when the plaintiff knew or should have known of the injury and its potential link to the drug. Given the delayed recognition of gastroparesis symptoms and their attribution to Ozempic, the timeline between exposure and documented harm is crucial. Patients who developed gastroparesis after starting Ozempic should seek legal counsel promptly to preserve their rights. Settlement negotiations may consider the strength of evidence linking Ozempic to gastroparesis, the adequacy of warnings, and the severity of the patient's condition. In summary, the evidence demonstrates a clear association between Ozempic use and gastrointestinal adverse reactions, including symptoms consistent with gastroparesis. The mechanistic plausibility, combined with clinical trial data, supports a causal link. However, the absence of explicit gastroparesis warnings in the label may be a factor in litigation. New York patients should be aware of the three-year statute of limitations and consult an attorney to evaluate their claims.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Ozempic gastroparesis claims in New York?

In New York, the statute of limitations for personal injury claims is generally three years from the date of injury. For product liability cases involving prescription drugs, the clock typically starts when the plaintiff knew or should have known of the injury and its potential link to the drug. Given the delayed recognition of gastroparesis symptoms, patients should consult an attorney promptly to preserve their rights.

Does Ozempic's label include a warning about gastroparesis?

The prescribing information for Ozempic includes warnings about gastrointestinal adverse reactions but does not explicitly list gastroparesis as a specific adverse event. This absence may be a factor in litigation regarding the adequacy of warnings. (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166)

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Ozempic exposure and a confirmed Gastroparesis diagnosis may request an independent eligibility review. [Begin Assessment]

References

DailyMed - Ozempic Label

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.